Pharmacodynamic modeling of chemotherapeutic effects: Application of a transit compartment model to characterize methotrexate effects in vitro
暂无分享,去创建一个
[1] W J Jusko,et al. Pharmacodynamic modeling of time‐dependent transduction systems , 2001, Clinical pharmacology and therapeutics.
[2] William J. Jusko,et al. A pharmacodynamic model for cell-cycle-specific chemotherapeutic agents , 1973, Journal of Pharmacokinetics and Biopharmaceutics.
[3] J. Lokich,et al. Dose intensity for bolus versus infusion chemotherapy administration: review of the literature for 27 anti-neoplastic agents. , 1997, Annals of oncology : official journal of the European Society for Medical Oncology.
[4] M. Karlsson,et al. Model for time dependency of cytotoxic effect of CHS 828 in vitro suggests two different mechanisms of action. , 2001, The Journal of pharmacology and experimental therapeutics.
[5] P. O'dwyer,et al. Phase I and pharmacokinetic study of the novel platinum analogue CI-973 on a 5-daily dose schedule. , 1992, Cancer research.
[6] J. Aisner,et al. A phase I trial of continuous infusion VP16-213 (Etoposide) , 2004, Cancer Chemotherapy and Pharmacology.
[7] M. Koyama,et al. An improved colorimetric assay for interleukin 2. , 1986, Journal of immunological methods.
[8] J. Bickers,et al. Dose schedule and antitumor studies of arabinosyl cytosine (NSC 63878). , 1969, Cancer research.
[9] W J Jusko,et al. Transit compartments versus gamma distribution function to model signal transduction processes in pharmacodynamics. , 1998, Journal of pharmaceutical sciences.
[10] R. Lipton,et al. Phase I clinical and pharmacokinetic study of taxol. , 1987, Cancer research.
[11] W R Greco,et al. Modeling of the time-dependency of in vitro drug cytotoxicity and resistance. , 1998, Cancer research.
[12] L B Sheiner,et al. Simultaneous modeling of pharmacokinetics and pharmacodynamics: application to d-tubocurarine. , 1980, Clinical pharmacology and therapeutics.
[13] W. Evans,et al. Clinical pharmacokinetics and pharmacodynamics of anticancer drugs in children. , 1993, Seminars in oncology.
[14] H. Maurer,et al. Growth kinetics of L1210 leukemic cells exposed to different concentration courses of methotrexate in vitro , 2004, Cancer Chemotherapy and Pharmacology.
[15] Varun Garg,et al. Comparison of four basic models of indirect pharmacodynamic responses , 1993, Journal of Pharmacokinetics and Biopharmaceutics.
[16] G. Peters,et al. Schedule-dependent antitumor effect of gemcitabine in in vivo model system. , 1995, Seminars in oncology.
[17] M. Karlsson,et al. Semiphysiological model for the time course of leukocytes after varying schedules of 5-fluorouracil in rats. , 2000, The Journal of pharmacology and experimental therapeutics.
[18] P. Langenberg,et al. Relationships between carboplatin exposure and tumor response and toxicity in patients with ovarian cancer. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] J. Wanders,et al. Population pharmacokinetics and pharmacokinetic‐pharmacodynamic relationships of the novel anticancer agent E7070 in four phase I studies , 2002 .
[20] L. Grochow. Busulfan disposition: the role of therapeutic monitoring in bone marrow transplantation induction regimens. , 1993, Seminars in oncology.
[21] N. Saijo,et al. Indirect‐response model for the time course of leukopenia with anticancer drugs , 1998, Clinical pharmacology and therapeutics.
[22] J. Madelmont,et al. Pharmacokinetic study of cystemustine, administered on a weekly schedule in cancer patients. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.
[23] S. Baker,et al. Clinical pharmacodynamics of continuous infusion topotecan in children: systemic exposure predicts hematologic toxicity. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[24] Y. Sasaki,et al. Pharmacodynamic Modeling of the Entire Time Course of Leukopenia after a 3‐Hour Infusion of Paclitaxel , 2001, Japanese journal of cancer research : Gann.
[25] J. Verweij,et al. Population Pharmacokinetics/Toxicodynamics (PK/TD) Relationship of SAM486A in Phase I Studies in Patients with Advanced Cancers , 2000, Journal of clinical pharmacology.
[26] W J Jusko,et al. Pharmacodynamics of chemotherapeutic effects: dose-time-response relationships for phase-nonspecific agents. , 1971, Journal of pharmaceutical sciences.
[27] M. Relling,et al. Conventional compared with individualized chemotherapy for childhood acute lymphoblastic leukemia. , 1998, The New England journal of medicine.
[28] T. Nakamura,et al. Evaluation of cell-killing effects of 1-beta-D-arabinofuranosylcytosine and daunorubicin by a new computer-controlled in vitro pharmacokinetic simulation system. , 1999, Cancer research.
[29] M. Terrissol,et al. Chronotoxicity of methotrexate in mice after intraperitoneal administration. , 1987, Chronobiologia.